New findings reveal Syfovre may protect central vision in macular degeneration patients, delaying vision loss and enhancing treatment strategies.

In July 2025, Novartis Pharmaceuticals conducted a study is to assess the effect of Iptacopan to prevent conversion of early ...

Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause ...

In July 2025, Novartis Pharmaceuticals organized a study is to assess the effect of Iptacopan to prevent conversion of early ...

Age-related macular degeneration (AMD) remains a leading cause of vision loss, but new therapies are reshaping its treatment.

Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration: Basel Monday, August 4, 2025, 11:00 Hrs [ ...

Gain insights into EyePoint Pharmaceuticals' Q2 2025 performance, featuring DURAVYU's Phase III progress in wet-AMD, global expansion, and ...

OCLI Vision, a Spectrum Vision Partners managed practice, is pleased to announce the addition of Dr. Maryam Ige, a highly ...

LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community – – ...

Pavblu, an Eylea HD biosimilar, shows stable vision outcomes and minimal side effects in real-world use, promising a reliable ...

In this Healio Video Perspective from the ARVO meeting, Michael Javaheri, MD, overviews real-world data on Eylea HD in ...